Stefani S, Mezzatesta M L, Tempera G, Debbra E, Schito A M, Nicoletti G, Marchére A
Department of Microbiological and Gynecologic Sciences, Section of Microbiology, University of Catania, Via Androne 81, 95124 Catania, Italy.
Clin Microbiol Infect. 2002 Jun;8(6):368-72. doi: 10.1046/j.1469-0691.2002.00429.x.
The activity of linezolid, a new oxazolidinone, was tested against 862 Gram-positive cocci isolated in Italy and compared with the activities of 12 antibiotics. Overall, MIC90s for linezolid (2-4 mg/L) indicated an in vitro activity comparable to that of vancomycin in methicillin-resistant Staphylococcus aureus (4 mg/L), S. epidermidis (2 mg/L) and methicillin-susceptible strains. Enterococcus faecalis strains were susceptible to linezolid (MIC90 2-4 mg/L), glycopeptides and beta-lactams. In E. faecium, only glycopeptides (MIC90 2 mg/L) and linezolid (MIC90 2 mg/L) were active. Linezolid was the only drug active against two strains of Enterococcus showing a VanA phenotype. Owing to its antibacterial profile, linezolid represents a promising drug for the treatment of Gram-positive infections.
对一种新型恶唑烷酮类药物利奈唑胺的活性进行了测试，该测试针对的是在意大利分离出的862株革兰氏阳性球菌，并与12种抗生素的活性进行了比较。总体而言，利奈唑胺的MIC90（2 - 4毫克/升）表明其体外活性与万古霉素在耐甲氧西林金黄色葡萄球菌（4毫克/升）、表皮葡萄球菌（2毫克/升）和甲氧西林敏感菌株中的活性相当。粪肠球菌菌株对利奈唑胺（MIC90 2 - 4毫克/升）、糖肽类和β-内酰胺类敏感。在屎肠球菌中，只有糖肽类（MIC90 2毫克/升）和利奈唑胺（MIC90 2毫克/升）有活性。利奈唑胺是唯一对两株呈现VanA表型的肠球菌有活性的药物。由于其抗菌谱，利奈唑胺是治疗革兰氏阳性感染的一种有前景的药物。
Zotero 插件